Comparison · NCT01597973-1a4feff1
Colistin and Placebo vs Colistin and a Carbapenem: Number of Participants Who Develop Colistin Resistance
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Colistin and Placebo vs Colistin and a Carbapenem: Number of Participants Who Develop Colistin Resistance. Trial comparisons, record NCT01597973-1a4feff1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01597973-1a4feff1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.104 | 0.0668 | 0.158 | wilson | |
| Risk in group 2 | 0.0867 | 0.0532 | 0.138 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0173 | -0.0461 | 0.0812 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.2 | 0.625 | 2.3 | log | |
| Odds ratio, group 1 over group 2 | 1.22 | 0.595 | 2.51 | log | |
| Number needed to treat, for one more participant with the outcome on Colistin and Placebo than on Colistin and a Carbapenem | 57.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Colistin and Placebo | colistin and placebo: colistin- loading dose standard, maintenance dose based on patient's renal function placebo- mimic meropenem (blinded) | 18 | 173 | OG000 |
| Group 2 | Colistin and a Carbapenem | colistin and a carbapenem: colistin standard loading dose, maintenance dose based on patient's renal function carbapenem- dose based on patient's renal function | 15 | 173 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Develop Colistin Resistance
- Description
Determine what treatment regimen (colistin monotherapy (combined with placebo)) or colistin combined a carbapenem (imipenem or meropenem) is more likely to reduce the frequency of emergence of colistin resistance among XDR-GNB isolates during therapy. Measurements of Minimum Inhibitory Concentration of colistin to XDR-GNB. This is shown below as numbers of those subjects who develop colistin resistance and their percentages of the total completed population.
- Time frame
- patients' resistance data will be collected up to 30 days
- Population
- Follow up cultures were unable to be obtained for some subjects. Therefore emergence of resistance status for those subjects could not be determined.
Source ClinicalTrials.gov
Trial
- Title
- Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
- NCT number
- NCT01597973
- Phases
- PHASE3
- Conditions
- Pneumonia, Blood Stream Infection
- Interventions
- colistin and meropenem, colistin and placebo
- Lead sponsor
- University of Michigan
- Results first posted
- 2021-11-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01597973?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01597973-1a4feff1